Summit Issuance Of Capital Stock from 2010 to 2025
| SMMT Stock | USD 21.43 0.56 2.68% |
Issuance Of Capital Stock | First Reported 2010-12-31 | Previous Quarter 477.9 M | Current Value 501.8 M | Quarterly Volatility 151.7 M |
Check Summit Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Summit Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18 M, Interest Expense of 9.1 M or Selling General Administrative of 63.6 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 48.03. Summit financial statements analysis is a perfect complement when working with Summit Therapeutics Valuation or Volatility modules.
Summit | Issuance Of Capital Stock | Build AI portfolio with Summit Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.